Method of carrier-free delivery of therapeutic RNA importable into human mitochondria: Lipophilic conjugates with cleavable bonds

Biomaterials

Volumn 76, Issue , 2016, Pages 408-417

  Dovydenko, Ilya ^a,b   Tarassov, Ivan ^a   Venyaminova, Alya ^b   Entelis, Nina ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

Author keywords

Antireplicative RNA; Cell delivery; Mitochondrial diseases; Mitochondrial drug delivery; RNA conjugates; RNA therapeutics

Indexed keywords

CELLS; CHOLESTEROL; CYTOLOGY; DNA; GENE THERAPY; MOLECULAR BIOLOGY; NUCLEIC ACIDS; OLIGONUCLEOTIDES; RNA;

CELL DELIVERY; CELLULAR COMPARTMENTS; MITOCHONDRIAL DISEASE; MITOCHONDRIAL GENOMES; MITOCHONDRIAL MATRIX; OLIGORIBONUCLEOTIDES; RNA CONJUGATE; RNA THERAPEUTICS;

MITOCHONDRIA;

HYDRAZONE DERIVATIVE; MITOCHONDRIAL DNA; OLIGORIBONUCLEOTIDE; RNA; SMALL UNTRANSLATED RNA; DRUG CARRIER;

ARTICLE; CONFOCAL MICROSCOPY; COVALENT BOND; HETEROPLASMY; HUMAN; HUMAN CELL; MITOCHONDRIAL GENOME; MITOCHONDRION; OSTEOSARCOMA; PRIORITY JOURNAL; SYNTHESIS; METABOLISM;

DRUG CARRIERS; HUMANS; MICROSCOPY, CONFOCAL; MITOCHONDRIA; RNA;

EID: 84961233517     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.075     Document Type: Article

References (45)

1. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 2012, 19:60-71.
2. Tavernier G., Andries O., Demeester J., Sanders N.N., De Smedt S.C., Rejman J. mRNA as gene therapeutic: how to control protein expression. J. Control Release 2011, 150:238-247.
3. Kolesnikova O., et al. Selection of RNA aptamers imported into yeast and human mitochondria. RNA 2010, 16:926-941.
4. Comte C., et al. Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome. Nucleic Acids Res. 2013, 41:418-433.
5. Ruiz-Pesini E., et al. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res. 2007, 35:D823-D828.
6. Wallace D.C. Mitochondrial DNA mutations in disease and aging. Environ. Mol. Mutagen. 2010, 51:440-450.
7. Taylor R.W., Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 2005, 6:389-402.
8. Tonin Y., et al. Modeling of antigenomic therapy of mitochondrial diseases by mitochondrially addressed RNA targeting a pathogenic point mutation in mitochondrial DNA. J. Biol. Chem. 2014, 289:13323-13334.
9. Zhou J., Shum K.T., Burnett J.C., Rossi J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharm. - Basel Switz. 2013, 6:85-107.
10. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 2006, 114:100-109.
11. Winkler J. Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 2013, 4:791-809.
12. Wolfrum C., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25:1149-1157.
13. Petrova N.S., et al. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res. 2012, 40:2330-2344.
14. Letsinger R.L., Zhang G.R., Sun D.K., Ikeuchi T., Sarin P.S. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:6553-6556.
15. West K.R., Otto S. Reversible covalent chemistry in drug delivery. Curr. Drug Discov. Technol. 2005, 2:123-160.
16. C. Yamada, A. Khvorova, R. Kaiser, E. Anderson, D. Leake. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference. Google Patents, (2013).
17. Tognolini M., et al. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem 2012, 7:1071-1083.
18. Zugates G.T., Anderson D.G., Little S.R., Lawhorn I.E., Langer R. Synthesis of poly(beta-amino ester)s with thiol-reactive side chains for DNA delivery. J. Am. Chem. Soc. 2006, 128:12726-12734.
19. Sugahara M., Uragami M., Yan X., Regen S.L. The structural role of cholesterol in biological membranes. J. Am. Chem. Soc. 2001, 123:7939-7940.
20. Bellon L. Oligoribonucleotides with 2'-O-(tert-butyldimethylsilyl) groups. Curr. Protoc. Nucleic Acid Chem. 2001, Chapter 3: Unit 3 6.
21. Dovydenko I., et al. Mitochondrial targeting of recombinant RNA. Methods Mol. Biol. 2015, 1265:209-225.
22. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9:671-675.
23. Rizk A., et al. Segmentation and quantification of subcellular structures in fluorescence microscopy images using Squassh. Nat. Protoc. 2014, 9:586-596.
24. Gowher A., Smirnov A., Tarassov I., Entelis N. Induced tRNA import into human mitochondria: implication of a host aminoacyl-tRNA-synthetase. PLoS One 2013, 8:e66228.
25. Hwang C., Sinskey A.J., Lodish H.F. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992, 257:1496-1502.
26. Balazs D.A., Godbey W. Liposomes for use in gene delivery. J. Drug Deliv. 2011, 2011:326497.
27. Rutz M., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 2004, 34:2541-2550.
28. de Fougerolles A.R. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 2008, 19:125-132.
29. Hope M.J. Enhancing siRNA delivery by employing lipid nanoparticles. Ther. Deliv. 2014, 5:663-673.
30. Meade B.R., et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol. 2014, 32:1256-1261.
31. Raouane M., Desmaele D., Urbinati G., Massaad-Massade L., Couvreur P. Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug. Chem. 2012, 23:1091-1104.
32. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid Res. 2011, 52:2111-2135.
33. Jaremko L., Jaremko M., Giller K., Becker S., Zweckstetter M. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 2014, 343:1363-1366.
34. De Haes W., Van Mol G., Merlin C., De Smedt S.C., Vanham G., Rejman J. Internalization of mRNA lipoplexes by dendritic cells. Mol. Pharm. 2012, 9:2942-2949.
35. Chen Q., et al. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J. Control Release 2010, 144:227-232.
36. Magnusson J.P., Fernandez-Trillo F., Sicilia G., Spain S.G., Alexander C. Programmed assembly of polymer-DNA conjugate nanoparticles with optical readout and sequence-specific activation of biorecognition. Nanoscale 2014, 6:2368-2374.
37. Varkouhi A.K., Scholte M., Storm G., Haisma H.J. Endosomal escape pathways for delivery of biologicals. J. Control Release 2011, 151:220-228.
38. Picard M., et al. Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4033-E4042.
39. Manea E.M., et al. Pearson syndrome in the neonatal period: two case reports and review of the literature. J. Pediatr. Hematol. Oncol. 2009, 31:947-951.
40. Kirby D.M., et al. Transmitochondrial embryonic stem cells containing pathogenic mtDNA mutations are compromised in neuronal differentiation. Cell Prolif. 2009, 42:413-424.
41. Shimizu A., et al. Mouse somatic mutation orthologous to MELAS A3302G mutation in the mitochondrial tRNA gene confers respiration defects. Biochem. Biophys. Res. Commun. 2015 Sep 14, pii: S0006-291X(15)30589-1. (Epub ahead of print). 10.1016/j.bbrc.2015.09.072.
42. Reddy P., et al. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 2015, 161:459-469.
43. Monnot S., et al. Segregation of mtDNA throughout human embryofetal development: m.3243A>G as a model system. Hum. Mutat. 2011, 32:116-125.
44. Fan W., et al. A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations. Science 2008, 319:958-962.
45. Nakada K., Hayashi J. Transmitochondrial mice as models for mitochondrial DNA-based diseases. Exp. Anim. 2011, 60:421-431.